Pooling data from the PROMINENT, REDUCE-IT, and STRENGTH trials, Paul Ridker and C. Michael Gibson discuss the residual inflammatory risks for patients treated with statins.
This program will address the rapidly evolving field of shunt therapy as a treatment for heart failure. Specific populations of heart failure where this therapy may be most applicable will be discussed, along with the specific shunt types currently being tested. Results from studies already reported will be reviewed, combined with a look at the short and longer-term horizons for this therapeutic category.
This CME-accredited program will focus on advancements in the management of severe aortic stenosis (AS). Current guidelines recommend symptom-based treatment; however, emerging data suggests earlier intervention could improve patient outcomes. Expert faculty will discuss evolving perspectives on AS therapy, including modern metrics, the risks of delayed intervention, and potential changes to guidelines.